Careers  |  Sign In  |  Register

Novel Anti-Seizure Drug Progresses Through Late-Stage Development

According to an article published by Reuters, a new drug developed by Sage Therapeutics, Inc to treat patients with super-refractory status epileptics (SRSE) is ready to enter the next phase in clinical study and trials. Current data reveals that the drug provoked a seventy-seven percent response rate from patients in a constant state of seizure. Currently, in the United States alone, two-thirds of the 25,000 SRSE patients die or become disabled each year. If this drug succeeds, it would be the first targeted therapy to treat this aggressive and highly fatal disorder and is predicted to potentially become commercially available by 2018.

Read the full article published by Reuters here.